Awaiting product image

Ihc – Breast Cancer Prognosis Profile # 5a (Er, Pr, Metastatic Marker-15.3)

₹4,000.00

15 minutes
Categories: ,

This diagnostic panel evaluates breast cancer tissue and blood for the following markers:

• ER (Estrogen Receptor): Assesses if cancer cells rely on estrogen to grow.
• PR (Progesterone Receptor): Determines if progesterone influences tumor growth.
• Metastatic Marker CA 15-3: A blood-based tumor marker used to monitor the presence or spread of breast cancer.

The combination of hormone receptor status and the metastatic marker provides a comprehensive profile that aids in diagnosis, treatment planning, and monitoring disease progression or recurrence.

Enquiry Here

    Description

    Why It’s Done:

    This test is performed to:
    • Classify the type of breast cancer based on hormone receptor status (ER/PR).
    • Guide hormone therapy decisions — cancers that are ER/PR positive often respond well to hormone-blocking treatments.
    • Monitor cancer recurrence or metastasis using CA 15-3, especially in advanced stages.
    • Evaluate treatment effectiveness in patients undergoing therapy for breast cancer.
    CA 15-3 is not used for initial diagnosis but is valuable in tracking the course of the disease over time.

    Preparation:

    • For ER/PR Testing: Requires a tissue sample from a biopsy or surgical specimen. No special patient preparation is needed.
    • For CA 15-3 Testing: A blood sample is required. Minimal preparation is needed, but your healthcare provider may recommend:
    o Fasting for a few hours (optional, depending on lab protocol)
    o Informing them of any medications or supplements being taken

    Related products